Antihypertensive drugs

https://www.inorganicventures.com/coa-sds-search

An inhibitor of EGFR and VEGFR tyrosine kinases (IC₅₀s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively) demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models.

An inhibitor of EGFR and VEGFR tyrosine kinases (IC₅₀s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively) demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models.

An inhibitor of EGFR and VEGFR tyrosine kinases (IC₅₀s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively) demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models.

An inhibitor of EGFR and VEGFR tyrosine kinases (IC₅₀s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively) demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models.

https://www.inorganicventures.com/coa-sds-search

https://www.inorganicventures.com/coa-sds-search

https://www.inorganicventures.com/coa-sds-search

https://www.inorganicventures.com/coa-sds-search

https://www.inorganicventures.com/coa-sds-search

β-Nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt hydrate.

β-Nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt hydrate.